EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities

Kinga Dyndał iD, Patrycja Pańczyszyn-Trzewik iD, Magdalena Sowa-Kućma iD

International Journal of Molecular Sciences · 08.09.2025 · 26 (17) · 8755

DOI: 10.3390/ijms26178755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.09.2025. Verfasst von Kinga Dyndał und 2 weiteren Autor:innen. Beteiligte Einrichtung: Student's Science Club of Physiology "NEURON", Faculty of Medicine, Collegium Medicum, University of Rzeszów, Kopisto 2a, 35-315 Rzeszów, Poland. Hauptthemen laut MEDLINE: Antidepressive Agents, Depression, Depressive Disorder. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish Ministry of Education and Science, Minister of Science, Medical College of Rzeszow University (Rzeszow, Poland).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Depressive disorder is the most prevalent mental illness, and increasing evidence suggests its potential bidirectional relationship with metabolic disorders. Given the limited efficacy of conventional antidepressants (including Selective Serotonin Reuptake Inhibitors; SSRIs) and the growing prevalence of treatment-resistant depression, there is a significant need to identify alternative molecular pathways underlying the pathophysiology of depressive disorder, which may represent novel therapeutic targets for other agents. Emerging evidence indicates that metabolic dysfunction and depressive disorder share a common pathophysiological molecular mechanism and increase each other’s risk. Targeting peripheral metabolic pathways and their interactions with the central nervous system may alleviate depressive symptoms. Glucagon-Like Peptide-1 agonists (GLP-1 RAs) and Sodium–Glucose Cotransporter-2 (SGLT2) inhibitors, widely used in the treatment of type 2 diabetes and obesity, exhibit neurotrophic and anti-inflammatory effects, ameliorate oxidative stress, and enhance mitochondrial function, collectively contributing to the antidepressant-like effects observed in preclinical studies. Peroxisome Proliferator-Activated Receptor (PPAR) α agonists primarily regulate lipid and glucose metabolism, which may potentially improve neuronal plasticity and mood regulation. Moreover, agents such as Angiotensin Receptor Blockers (ARBs) and Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), used in hypertension treatment, exert central anti-inflammatory and neuroprotective effects via the modulation of the renin–angiotensin–aldosterone system (RAAS), implicated in affective disorders. Nevertheless, long-term, head-to-head trials are required to establish their efficacy, safety, and therapeutic positioning within current treatment paradigms. The aim of this review is to summarize current evidence on metabolic modulators as potential antidepressant strategies, focusing on their molecular mechanisms, preclinical and clinical findings, and prospects for integration into future therapies for depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsDepressionDepressive DisorderHumansAnimalsSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

GLP-1R agonistsPPARα agonistsRAA modulatorsSGLT2 inhibitorsdepressive disordermetabolic diseases

Substanzen

Antidepressive AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Student's Science Club of Physiology "NEURON", Faculty of Medicine, Collegium Medicum, University of Rzeszów, Kopisto 2a, 35-315 Rzeszów, Poland.
  • Department of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzeszów, Al. Tadeusza Rejtana 16C, 35-959 Rzeszów, Poland.
  • Centre for Innovative Research in Medical and Natural Sciences, Collegium Medicum, University of Rzeszów, Warzywna 1a, 35-310 Rzeszów, Poland.

ORCID-Profile: Kinga Dyndał, Patrycja Pańczyszyn-Trzewik, Magdalena Sowa-Kućma

Förderung

  • Polish Ministry of Education and Science
  • Minister of Science
  • Medical College of Rzeszow University (Rzeszow, Poland)

Zitieren

APA

Dyndał, K., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2025). Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities. International Journal of Molecular Sciences, 26(17), 8755. https://doi.org/10.3390/ijms26178755

Vancouver

Dyndał K, Pańczyszyn-Trzewik P, Sowa-Kućma M. Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities. International Journal of Molecular Sciences. 2025;26(17):8755. doi:10.3390/ijms26178755

BibTeX
@article{Dynda2025,
  author = {Dyndał, Kinga and Pańczyszyn-Trzewik, Patrycja and Sowa-Kućma, Magdalena},
  title = {Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8755},
  doi = {10.3390/ijms26178755}
}
Kostenlos starten →